MedTrace Logo

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

NCT04902807 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-09-08

No results posted yet for this study

Summary

The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).

Conditions

  • Autoimmune Lymphoproliferative Syndrome
  • Autoimmune Cytopenia
  • Autoimmune Diseases
  • Autoimmune Anemia
  • Autoimmune Thrombocytopenia
  • Autoimmune Hepatitis
  • Autoimmune Diabetes
  • Autoimmune Rheumatologic Disease
  • Systemic Lupus Erythematosus
  • Juvenile Idiopathic Arthritis
  • Hemophagocytic Lymphohistiocytoses
  • EBV Lymphoproliferation
  • RAS-Associated Autoimmune Leucoproliferative Disease
  • Primary Immunodeficiency
  • APECED
  • IPEX
  • BENTA
  • Enteropathy, Autoimmune
  • Combined Immunodeficiency
  • IBD

Interventions

BIOLOGICAL

Collection of samples

Blood, Urine and Stool samples will be collected from the participants.

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    lead OTHER_GOV

Principal Investigators

  • Frédéric Rieux-Laucat · Institut Imagine

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2025-05-14
Completion
2026-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04902807 on ClinicalTrials.gov